Clinical Trial Update: A Community Setting Study of Malaria After Systematic Treatment of Symptomatic Carriers of P. Falciparum With COA566 (Coartem®) [Phase 4]

View source ↗

Summary

Phase 4 community-setting trial evaluating outcomes after systematic treatment with COA566 (Coartem) in symptomatic carriers of malaria due to Plasmodium falcip…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• Coartem (artemether-lumefantrine)

Snippet

Sponsor: Novartis | Conditions: Malaria | Phase 4 | Status: COMPLETED | Results posted: 2013-11-25